7/26/2019 AHEL Investor Presentation Dec 14
1/32
June 25, 2015
7/26/2019 AHEL Investor Presentation Dec 14
2/32
2
7/26/2019 AHEL Investor Presentation Dec 14
3/32
3
7/26/2019 AHEL Investor Presentation Dec 14
4/32
4
7/26/2019 AHEL Investor Presentation Dec 14
5/32
64%
34%
2%
7,207 2,008 9,215 44 11 55
6,200+ 10,000+ 3,400+
1,822
Shareholding(1): Promoters (34.4%), FIIs & FCBs (55.6%), MF/FI/IC (2.0%),Others (8.0%)
Market capitalization of` 190,490 mn(4) and Debt to Equity ratio of 0.52x(1)
Health Insurance (AHEL stake 10.2%)
Primary Clinics
Sugar Clinics
Birthing centres CRADLE
Day Care Centres
across 21 states
(1) As on 31st Mar 2015.(4) NSE Closing price on 31st Mar 2015Source: Company audited financials and Q4FY15 Earnings Update. # Source: Frost & Sullivan
146
5
(2)All financial are for fiscal year (FY) ended March 31. (3) Fx used: US$1= ` 63.
* FY15 info for owned hospitals only. Does not include managed hospitals
350,000+
Admissions
3,200,000+
Out-Patients
250,000
Preventive HealthChecks
11,000+
HeartSurgeries
5,000+
JointReplacements
14,000+
Neuro SurgicalOperations
500
RoboticSurgeries
1,100+
KidneyTransplants
400+
LiverTransplants
120
CountriesMedical Value
Travel
170
Bone MarrowTransplants
155,000+Radiotherapy
Sessions
47,000+Chemotherapy
Sittings
FY15 at Apollo Hospitals*
FY10 FY11 FY12 FY13 FY14 FY15
Gross Revenue(`mn) 20, 265 26, 054 31, 475 37,687 43, 842 51, 785
Gross Revenue($ mn)(3)
322 414 500 598 696 822
YoY Growth 25.50% 28.60% 20.80% 19.70% 16.30% 18.12%
EBITDA 3,013 4,190 5,131 6,082 6,724 7,347
EBITDA Margin 14.90% 16.10% 16.30% 16.10% 15.30% 14.19%
Profit A ft er Tax (P AT) 1, 376 1,839 2,194 3, 044 3, 168 3,399
PAT Margin 6.80% 7.10% 7.00% 8.10% 7.20% 6.56%
Net Worth 16,776 19,238 25,194 27,641 29,955 32,443
Total Loans 9,132 9,585 8,183 12,179 13,601 20,142Cash and Cash
Equivalents 3,117 2,664 3,588 6,842 4,151 4,833
7/26/2019 AHEL Investor Presentation Dec 14
6/32
# of Beds: 9,215# of Hospitals: 55
# of Beds: 5,100# of Hospitals: 54
# of Beds: 2,078# of Hospitals: 15
# of Beds: 7,452# of Hospitals: 29
# of Beds: 5,118
# of Hospitals: 15
# of Beds: 1,103# of Hospitals: 7
# of Beds: 2,016# of Hospitals: 10
# of Beds: 1,250# of Hospitals: 1
Source: Company Reports, CRISIL Research # Beds as on 31st March 2015.* Fortis corporate presentation as of April 2015, publicly available on Fortis Healthcare Ltd.s website.
6
Owned BedsCAGR (FY05-15)
9.2%
Capacity Beds Operational No. of Hospitals
Category Wise
Owned 7,207 6,321 44
Managed 2,008 2,008 11
Grand Total 9,215 8,329 55
Cluster Wise (Owned)
Chennai 1,718 1,495 13
Hyderabad 959 930 7
Kolkata 540 540 2
Delhi 875 713 2
Bangalore 499 378 2Ahmedabad 320 274 2
Tamilnadu
(outside Chennai) 808 589 4
Bhubaneswar 290 264 1
Other India 1,198 1,138 11
Grand Total 7,207 6,321 44
Maturity Wise (Owned)
> 5 years 4,406 4,334 24
3 - 5 years 957 773 7
1 - 3 years 1,136 740 6
< 1 year 708 474 7
Grand Total 7,207 6,321 44
*
Source: Company MIS Reports,
7/26/2019 AHEL Investor Presentation Dec 14
7/32
7
7/26/2019 AHEL Investor Presentation Dec 14
8/32
8
2011 Apollo Day Care Surgery facility for minor surgeries
requiring short stay. Hospital atKaraikudi, Tamil Nadu
2013 Hospitals in Vanagaram(Chennai), Jayanagar(Bengaluru) & Trichy
2015 Hospitals in Nashik, Nellore,Women & child centers atKarapakkam & SMR, OMRPerungudi
2011 Apollo Institute of RoboticSurgery launched - the firstrobotic centre in Tamil Nadu
2012 Placed order for Proton therapyequipment for Cancer treatment
2013 Apollo Health City, Hyderabadperforms Minimally InvasiveKnee Replacement (Resurface)Surgery using OrthoGlideMedial Knee system
2011-2015
FY2015
9,215 beds
1,822 stores
Revenues 51,785 mn.
7/26/2019 AHEL Investor Presentation Dec 14
9/32
9
7/26/2019 AHEL Investor Presentation Dec 14
10/32
10
7/26/2019 AHEL Investor Presentation Dec 14
11/32
11
In order to meet the global median of 30 beds per 10,000 population, India will need to invest over 14 trillion ($230 bn)
Source: CRISIL Research
7/26/2019 AHEL Investor Presentation Dec 14
12/32
12
7/26/2019 AHEL Investor Presentation Dec 14
13/32
13
7/26/2019 AHEL Investor Presentation Dec 14
14/32
14
7/26/2019 AHEL Investor Presentation Dec 14
15/32
15
7/26/2019 AHEL Investor Presentation Dec 14
16/32
16
Service
Excellence
Guest Relation Apollo has adopted the engagement
Pathway for Voice of Customer (VOC) Partnered with Gallup to benchmark
e-customer feedback with best in classhospitals globally
In-house framework captures VOCfrom Interactions and converts theminto Qualitative and quantitativefeedback for quick follow-up action
Awarded Best Innovation in servicedelivery In 2013 by AIMA & HospitalsManagement Awards
Tender Loving Care Core training module for all
nurses
Inspires the conversion of dailyinteractions into memorableexperiences, resulting inenhanced courtesy index fornursing
Tender Loving Care (TLC) -Training for frontline staff
TLC acknowledge as BestTraining Initiative in Healthcareat Asian Learning &Development Leadership
Awards In Dubai in 2013
Human Sigma 1st in India to adopt Human Sigma by
mapping customer and employeeengagement to the Gallup SMethodology
Ranked this year among top 37companies that partner with Gallup
This recognises exceptional leadershipthat understands that engagingemployees drives real businessoutcomes
Apollo now among globally recognisedorganisation for mastering how to engageworkforce to deliver sustainable growth
Admissions Minimises waiting
time for plannedadmissions
Dedicated roomingexperience thatorients patients andattendees tovarious hospitalsservices
Discharge Post-discharge calls to patients for
suggestions and feedback 72hours after discharge
Speedy discharge summary forplanned discharges
7/26/2019 AHEL Investor Presentation Dec 14
17/32
17
7/26/2019 AHEL Investor Presentation Dec 14
18/32
1818
Healthcare services: Improvement in operating metrics Strong continued revenue growth in mature clusters
New Hospitals driving substantial revenue growth through quickramp up
Standalone Pharmacies: Revenue growth andmargin improvement Standalone pharmacies reported a positive EBITDA for each of the
last five years FY11, FY12, FY13, FY14 & FY15
All stores are in the growth phase with relatively mature stores growing
at a consistent rate with increasing EBITDA margins improvement in first year store performance due to better ramp-up
and lower losses
7/26/2019 AHEL Investor Presentation Dec 14
19/32
19
7/26/2019 AHEL Investor Presentation Dec 14
20/32
20
7/26/2019 AHEL Investor Presentation Dec 14
21/32
Indias largest organized pharmacy retail chain with a network of 1,822 stores.
21
Asset light business model with an established track record
Presence in metro centers such as Hyderabad, Chennai,Bengaluru, Pune, Ahmedabad and NCR regions
Offers a wide range of medicines and surgical products, hospitalconsumables and over-the-counter products
Own brand private labels (FMCG & OTC drugs) constitutes over6% of FY14 turnover. Target to increase to 20% in next 5 years
Introduced generic and in-house brands (Private Labels)
Consistent growth in standalone pharmacy revenue
Calibrated rollout: 190 stores opened in FY15, 129 stores opened inFY14, 139 stores opened in FY13, 165 stores opened in FY12, 150 inFY11 and 166 in FY10
Increased penetration of private label sales
Integrate supply chain network and optimize inventory levels
Emphasis on margin improvement
Mature cohort of pre-2008 stores have achieved 5.9% EBITDAmargins in FY15
Positive overall EBITDA margin FY 11 , FY 12, FY13, FY14 & FY15
Regulatory Update: In September 2012, the Central Governmentapproved the DIPP proposal to permit 51% FDI in multi-brandretail, subject to certain conditions
7/26/2019 AHEL Investor Presentation Dec 14
22/32
Revenue growth of18.1% from ` 43,842 mn in FY 14 to` 51,785 mn in FY 15
Consolidated EBITDA grew by 9.3% % from` 6,724 mn in FY 14 to` 7,347 mn in FY 15
Consolidated PAT grew 7.3% from ` 3,168 mn in FY14 to ` 3,399 mn in FY15
(1) Capital employed for the calculation of ROCE does not include Capital Work in progress on newhospital expansion projects of` 5,122 mn for FY15 and ` 4,810 mn for FY14 & investments inmutual funds and associates
Previous year figures have been reworked/regrouped/rearranged and reclassified wherevernecessary to conform to the requirement of revised Schedule VI format
JVs include Ahmedabad50%, Kolkata50% ,PET CT50%, Apollo Munich10.23%,Quintiles40%, Apollo Lavasa37.50% , Future Parking Pvt Ltd49% and Apokos Rehab Pvt Ltd -50%
FY 15: financial performance
Revenues of` 45,928 mn, 18.9% yoy growth
EBITDA at ` 6,781 mn, 10.5% yoy growth
EBIT at ` 5,200 mn, 7.3% yoy growth
Higher Depreciation due to application of higher depreciation rates as per theNew Companies Act & New Units Nashik and Women & Child, OMR
PAT at ` 3,466 mn, 4.8% yoy growth
22
``
FY 14 FY 15 yoy (%)
Revenue 38,616 45,928 18.9%
Operative Expenses 20,019 24,240 21.1%
Employee Expenses 6,102 7,210 18.1%
Administrative & Other Expenses 6,357 7,698 21.1%
Total Expenses 32,478 39,147 20.5%
EBITDA 6,139 6,781 10.5%
margin (%) 15.9% 14.8% -113 bps
Depreciation 1,291 1,580 22.4%
EBIT 4,848 5,200 7.3%margin (%) 12.6% 11.3% -123 bps
Financial Expenses 871 833 -4.3%
Other Income/ Except ional item * 225 306 36.2%
Profit Before Tax 4,202 4,673 11.2%
Profit After Tax 3,307 3,466 4.8%
margin (%) 8.6% 7.5% -102 bps
ROCE (Annualized) 14.6% 12.8%
Capital Employed(1) 33,205 40,703
FY 14 FY 15 yoy (%)
Income from Operations 41,113 48,705 18.5%
Add: Share of JVs 2,730 3,079 12.8%
Total Revenues 43,842 51,785 18.1%
EBITDA 6,724 7,347 9.3%
margin(%) 15.3% 14.2% -115 bps
EBIT 5,046 5,230 3.6%
margin (%) 11.5% 10.1% -141 bps
Profit After Tax 3,168 3,399 7.3%
margin (%) 7.2% 6.6% -66 bps
Total Debt 20,142
Cash & Cash equivalents
(includes investment in liquid funds)
4,833
7/26/2019 AHEL Investor Presentation Dec 14
23/32
Healthcare
services
(Existing)
New
Hospitals
Healthcare
services
(Total) SAP Standalone
Total
Healthcare
Services
(Existing)
New
Hos pitals SAP
Munich
(AHEL
stake 10%)
AHLL
(incl.
Cradle) Consol idated
FY 15
Revenue 26,435 1,767 28,202 17,726 45,928 30,483 1,767 17,726 735 1,074 51,785
EBITDA 6,276 (75) 6,200 580 6,781 7,124 (75) 580 10 (292) 7,347
margin (%) 23.7% 22.0% 3.3% 14.8% 23.4% 3.3% 1.3% 14.2%
EBIT 5,111 (300) 4,811 390 5,200 5,574 (300) 390 2 (435) 5,230
margin (%) 19.3% 17.1% 2.2% 11.3% 18.3% 2.2% 0.3% 10.1%
FY 14
Revenue 24,437 531 24,968 13,648 38,616 28,312 531 13,648 607 743 43,842
EBITDA 5,900 (210) 5,690 449 6,139 6,688 (210) 449 (30) (172) 6,724
margin (%) 24.1% 22.8% 3.3% 15.9% 23.6% 3.3% 15.3%
EBIT 4,838 (333) 4,505 343 4,848 5,330 (333) 343 (37) (257) 5,046
margin (%) 19.8% 18.0% 2.5% 12.6% 18.8% 2.5% 11.5%
YoY Growth
Revenue 8.2% 232.7% 13.0% 29.9% 18.9% 7.7% 232.7% 29.9% 21.0% 44.4% 18.1%
EBITDA 6.4% NA 9.0% 29.4% 10.5% 6.5% NA 29.4% NA NA 9.3%
EBIT 5.6% NA 6.8% 13.7% 7.3% 4.6% NA 13.7% NA NA 3.6%
FY 15: financial performance
23
``
7/26/2019 AHEL Investor Presentation Dec 14
24/32
Chennai & Hyderabad clusters
Chennai cluster revenue growth of 12.1% Revenue growth of 8.5% in Hyderabad
Others driving substantial growth (17.2%) focus on Inpatient revenue growth (17.3%). 16.6% growth in OP Revenues. Significant Subsidiary / JV & Associate Hospitals Revenue growth of 10.3%. 8% yoy growth in Bangalore & 6% yoy growth in Ahmedabad and 13% yoy growth
in Kolkata.
Notes:(1) Others include Madurai, Karur, Karaikudi, Trichy, Mysore, Vizag, Pune, Karimnagar, Bilaspur, Bhubaneswar, Jayanagar,Nashik & Nellore.(2) Significant Hospital JVs/Subs/Associates are Ahmedabad, Bangalore, Kolkata, Kakinada, Delhi & Indore(full revenues shown in table above).(3) Outpatient volume represents New Registrations only.(4) ARPOB and Net Revenue is net of doctor fees.(5) Revenues under the head Total have not been provided as Consolidated actual results will differ from Total due to proportionate consolidation.* Inpatient volumes are based on discharges.** Previous year financial and operational numbers have been regrouped and reclassified wherever necessary to conform with current year classification and full year audited numbers.
24
Total(5) Chennai cluster Hyderabad cluster Others(1) Significant subs/JVs/
associates(2)
Particulars FY 14 FY 15 yoy ( %) FY 14 FY 15 yoy ( %) FY 14 FY 15 yoy (%) FY 14 FY 15 yoy (%) FY 14 FY 15 yoy (%)
No. of Operating beds 5,811 6,321 1,264 1,491 930 930 1,585 1,821 2,032 2,079
Inpatient v olume 331,678 353,547 6.6% 75,931 81,920 7.9% 51,048 51,877 1.6% 78,757 87,834 11.5% 125,942 131,916 4.7%
Outpatient volume(3) 1,132,618 1,244,192 9.9% 351,195 381,931 8.8% 152,495 161,717 6.0% 231,102 257,174 11.3% 397,826 443,370 11.4%
Inpatient ALOS (days) 4.54 4.43 4.35 4.43 4.49 4.15 5.00 4.80 4.39 4.30
Bed Occupancy Rate (%) 71% 68% 72% 67% 67% 63% 68% 63% 74% 75%
Inpatient revenue (`mn) NA NA 8,372 9,273 10.8% 3,763 4,066 8.1% 4,573 5,364 17.3% 11,901 13,063 9.8%
Outpatient revenue (`mn) NA NA 2,717 3,161 16.3% 820 905 10.4% 810 944 16.6% 2,237 2,537 13.4%
ARPOB (`/ day)(4) 23,684 25,381 7.2% 33,561 34,266 2.1% 20,002 23,081 15.4% 13,662 14,953 9.5% 25,590 27,506 7.5%
Total Net Revenue (`mn)(4) NA NA 11,089 12,433 12.1% 4,582 4,971 8.5% 5,383 6,308 17.2% 14,137 15,600 10.3%
7/26/2019 AHEL Investor Presentation Dec 14
25/32
FY 15 Revenues EBITDA
EBITDA Margins # of Stores 31 Mar15
`17,726 mn
30% yoy growth
`580 mn
FY15
`449 mn
FY14
3.3%
FY14
3.3%
FY15
Added 242
Closed 52
Total 1,822FY
15
Like-for-like Revenue per store growth
14.3% (yoy)
pre FY08batch of stores
20.0% (yoy)
FY09batch
ROCE
~ 18%
mature stores
pre FY08 batch
Gross addition of
53 stores
and closed
15 in Q4FY15
EBITDA margins
5.9%
mature storespre FY08 batch
SAP revenue
grew by 29.9%
EBITDA margins
3.3%
25
`
Batch Particulars FY 14 FY 15 yoy (%)
Upto FY08 Batch No. of Stores 434 425
Revenue/Store 11.63 13.30 14.3%
EBITDA/Store 0.66 0.78 19.2%
EBITDA Margin % 5.6% 5.9% 24 bps
FY09 Batch No. of Stores 193 189
Revenue/Store 10.23 12.27 20.0%
EBITDA/Store 0.30 0.46 52.0%
EBITDA Margin % 2.9% 3.7% 79 bps
FY10 Batch No. of Stores 184 175
Revenue/Store 9.13 10.95 20.0%
EBITDA/Store 0.38 0.50 30.8%
EBITDA Margin % 4.2% 4.6% 38 bps
Total No. of Stores 1,632 1,822
Revenue/Store 8.36 9.68 15.8%
EBITDA/Store 0.27 0.32 16.6%
EBITDA Margin % 3.3% 3.3%2 bps
Total Revenues 13,648 17,726 29.9%
EBITDA 449 580 29.4%
EBITDA Margin % 3.3% 3.3% -1 bps
Capex (`mn) 161 222
Capital Employed (`mn) 3,336 5,299
ROCE (Total) 9.8% 6.8%
7/26/2019 AHEL Investor Presentation Dec 14
26/32
26
7/26/2019 AHEL Investor Presentation Dec 14
27/32
Cluster strategyfor expansion
with Greenfieldprojects inattractive newermarkets
We are focused on a Two pronged strategy on Healthcare services :
Ensure continued dominance by expanding into key existing clustersof Chennai, Bangalore,
Hyderabad, Kolkatta, Delhi and AhmedabadPlanned expansion in metros like Mumbai & large cities like Pune etcwith no existingpresence reaching to wider urban population
Grow laterally in high potential Tier II cities Expansion through REACH hospitals, first moveradvantage & leveraging the Apollo brand
Focus on Centersof Excellencewith one or two
anchorspecialties ineach market.
Oncology agrowing areaacross.
Each of our key clusters besides being built around a quaternary care hospital, focus on oneor two key specialties and build centers of excellence around that specialty
Aim to gain significant market share in each of the key specialties
Set benchmark standards in clinical outcomes, technology and practices in select acute and tertiarycare services Cardiology, Oncology, Neurosciences, Critical Care, Orthopedics andTransplants (CONECT)
Extend and expand our oncology presence both thru specialization and exclusive oncologyreferral hospitals in the clusters. 200 bedded Cancer referral center under construction inChennai with Proton Therapy
well planned strategy to deliver the next phase of growth
27
Increase Presencein Indian Healthcare
Retail Space &calibrated expansionin StandalonePharmacies
Retail Healthcare : Increase our presence and reach across all markets through retail healthcare(Clinics, Sugar Clinics, Dental, Cradle & Dialysis) and Day Surgery centersthrough our Clinic
subsidiary - AHLL
Standalone pharmacy business - Calibrated expansion plans with focus on same store growth,increased private label sales and margin improvement
7/26/2019 AHEL Investor Presentation Dec 14
28/32
Strong DoctorengagementModel and use oftechnology
guided by ourClinicalexcellence focus
Doctor engagement and Clinical focus probably is one of our core strengths.Doctor engagement model to be based on building group practice in key specialties withcombination of incentives based on revenue share/ profit share
Pioneers in use of technology to build robust health care systemscapable of addressing
diverse patient needs and changing disease profile Da Vinci Robotics in 4 locations, Truebeam ,NOVALIS, Cyber Knife, PET-CT, PET-MRI, ECMO, E-ICU etc.
Optimise AssetUtilisation inflagship facilities& locations
Enhance Out-Patients focus by creating value differentiators and leveraging on personalisedhealth checks advantage with the aim of increasing topline contribution from out-patients
Garner higher market share in select acute and tertiary care services
Specific plan to further penetrate deeper into Cardiology, Neurosciences & Oncology
Focus on time-to-serve and service standards
Stabilise newfacilities andcompress time-to-maturity ofplanned capacityexpansions
Bhubaneswar: Currently at 80%+ occupancy over 15% ROCE; Currently focused on: Enhancingspecialization mix and adding Oncology
Hyderabad and Bangalore: New capacity additions being utilised for high-end tertiary care;Recruitment of specialist consultants for COEs
Shorter time-to-maturity is being planned for new facilities like:Vanagaram (260 beds),Jayanagar (140 beds), Trichy (200 beds), Nashik (100 beds), Nellore (200 beds), OMR (170 beds)
Cost Efficienciesand Focus onImproving KeyOperating Metrics
Optimised asset utilisationsand minimum waste of all resources thorough standardised SOPsand Lean Management
Higher patient turnover by reducing average length of stay and optimised ward processes forfaster turnaround time of all diagnostic process
Improving average revenue per bed day through richer case mix
28
7/26/2019 AHEL Investor Presentation Dec 14
29/32
* Expected date of completion updated as of June 25, 2015# Standalone financials as on 31st Mar 2015
29
Total funding requirement
16,626 mn(already invested
4,580 mn)
new projects investment & funding
Significant headroom
to raise capitaldebt equity ratio 0.52x #
debt EBITDA 2.48x #
Gross Debt
16,810 mn #
Cash & Cash equivalents
3,571 mn #
Net Debt
13,239 mn #
Location CoD* Type of Hospital No. of
Beds
Total Estimated
Project Cost
(`mio)
AHELs Share
of Cost
(`mio)
Additions in FY16
Navi Mumbai FY16 Super Specialty 350 4,374 4,374
North Bangalore FY16 Super Specialty 180 925 925
Vizag FY16 Super Specialty 250 1,494 1,494
MLCP FY16 400 83
Chennai-Main (Expansion) FY16 Super Specialty 30 100 100
Indore (expansion) FY16 Super Specialty 65 280 50Sub Total 875 7,573 7,026
Additions in FY19
South Chennai FY19 Super Specialty 175 2,000 2,000
Proton FY19 4,200 4,200
Byculla, Mumbai FY19 Super Specialty 300 1,400 1,400
Patna FY19 Super Specialty 240 2,000 2,000
Sub Total 715 9,600 9,600
Total 1,590 17,173 16,626
7/26/2019 AHEL Investor Presentation Dec 14
30/32
30
7/26/2019 AHEL Investor Presentation Dec 14
31/32
Dr. Prathap C.Reddy
Executive Chairman, Founder(M.D, MBBS, FCCP, FICA and FRCS)
Conferred the Padma Vibhushan in 2010
Conferred the Padma Bhushan in 1991
Spent 28 years with Apollo Hospitals
Dr. Preetha Reddy Executive Vice Chairperson
On the Board since the year 1989
Suneeta Reddy Managing Director
On the Board since the year 2000
Shobana Kamineni Executive Vice Chairperson, on the Board since2010
Over 20 years of experience in the healthcareindustry
Sangita Reddy Joint Managing Director, on the Board since2000
Received Young Manager of the year 1998award from Hyderabad Management Association
Was a member of the Prime Ministers delegationto Malaysia organized by the CII
N. Vaghul Independent Director, on the Board since2000
Conferred the Padma Bhushan in 2009
Deepak Vaidya Independent Director, on the Board since2000
Chairman of the Audit committee
Sanjay Nayar Independent Director on the Board
Vinayak Chatterjee Independent Director on the Board,
Chairman of Feedback Infra Pvt Ltd
Other IndependentDirectors
G Venkatraman, Habibullah Badsha, RafeequeAhamed and Rajkumar Menon
K. Padmanabhan Group President and has been with the companysince 1996
Responsible for business and strategic initiativesacross the group
S. K. Venkataraman Chief Strategy Officer and has been with thecompany since 1991
Served as the Chief Financial Officer andCompany Secretary of the Company since2002
Responsible for strategic initiatives across thegroup
KrishnanAkhileswaran
Chief Financial Officer and has been with theCompany since 2010
Over 15 years of experience in the field ofFinance
Responsible for the finance function of theCompany and its subsidiaries
Anne MarieMoncure
Chief Executive Officer Southern RegionResponsible for hospital operations of theSouthern Region
Dr. K. Hariprasad Chief Executive Officer Central Division andhas been with the Company since 1999
Responsible for hospital operations for theCentral Region
Dr. Rupali Basu Chief Executive Officer Eastern Region and has
been with the Company since 2008 Responsible for hospital operations of the
Eastern Region
Jacob Jacob Chief People Officer of the Company
Responsible for people initiatives over 12 yearsof experience
ArvindSivaramakrishnan
Chief Information Officer of the Company
Responsible for driving IT initiatives andprojects
31
7/26/2019 AHEL Investor Presentation Dec 14
32/32